ArticleCureus2025
Intravitreal Faricimab for the Management of Bilateral Macular Neovascularization Secondary to Macular Telangiectasia Type 2.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macular telangiectasia type 2 (MacTel2) is a bilateral neurodegenerative disease characterized by telangiectasia of macular vasculature and foveal atrophy that is typically acquired during middle age. It may lead to visual loss due to progressive reduction of photoreceptor function or secondary to macular neovascularization. We report a case of bilateral macular neovascularization associated with MacTel2, which was treated with intravitreal faricimab injections. A 52-year-old female presented with a history of progressive reduction of vision in both eyes. Dilated fundus examination revealed the presence of perifoveal telangiectasia and right-angled venules in the juxtafoveal region. Diagnosis of MacTel2 and associated macular neovascularization (MNV) was confirmed with fundus fluorescein angiography (FA), optical coherence tomography (OCT), and angiography (OCTA). The patient was treated with three bilateral injections of faricimab on a monthly basis. Following the last injection, there was improvement of best corrected visual acuity (BCVA), reduction of macular thickening on OCT, and shrinkage of the MNV on OCTA. This is the first reported case of usage of intravitreal injection of faricimab for the management of visual loss due to macular neovascularization due to MacTel2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.